BioSpace

UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years

The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.

By BioSpace

1 min read
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights